2,4′-dibromoacetophenone

Names

[ CAS No. ]:
99-73-0

[ Name ]:
2,4′-dibromoacetophenone

[Synonym ]:
2-Bromo-1-(4-bromophenyl)ethanone
BromophenacylBromide
PBPB
2,4'-Dibromoacetophenone
p-Bromophenacyl bromide
2-bromo-1-(4-bromophenyl)-1-ethanone
Ethanone, 2-bromo-1- (4-bromophenyl)-
2-bromo-4'-bromoacetophenone
2,4`-Dibromoacetophenone
2,4'-Dibromo-acetophenone
α,p-Dibromoacetophenone
Ethanone, 2-bromo-1-(4-bromophenyl)-
2,3-DIFLUOROBENZOTRIFLUORIDE
2,4′-dibromoacetophenone
MFCD00000200
p-α-Dibromoacetophenone
2-bromo-1-(4-bromophenyl)ethan-1-one
EINECS 202-783-6
p-bromophenacyl-8

Chemical & Physical Properties

[ Density]:
1.8±0.1 g/cm3

[ Boiling Point ]:
310.4±22.0 °C at 760 mmHg

[ Melting Point ]:
108-110 °C(lit.)

[ Molecular Formula ]:
C₈H₆Br₂O

[ Molecular Weight ]:
277.941

[ Flash Point ]:
114.1±8.9 °C

[ Exact Mass ]:
275.878540

[ PSA ]:
17.07000

[ LogP ]:
2.95

[ Vapour Pressure ]:
0.0±0.7 mmHg at 25°C

[ Index of Refraction ]:
1.604

[ Stability ]:
Stable. Incompatible with strong bases, strong reducing agents, strong oxidizing agents.

MSDS

Click to get detail MSDS

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: AM6950000

CHEMICAL NAME :: Acetophenone, 2,4'-dibromo-

CAS REGISTRY NUMBER :: 99-73-0

BEILSTEIN REFERENCE NO. :: 0607604

LAST UPDATED :: 199709

DATA ITEMS CITED :: 4

MOLECULAR FORMULA :: C8-H6-Br2-O

MOLECULAR WEIGHT :: 277.96

WISWESSER LINE NOTATION :: E1VR DE

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: >2 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: MEXPAG Medicina Experimentalis. (Basel, Switzerland) V.1-11, 1959-64; V.18-19, 1968-69. For publisher information, see JNMDBO. Volume(issue)/page/year: 11,137,1964

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 18 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: CSLNX* U.S. Army Armament Research & Development Command, Chemical Systems Laboratory, NIOSH Exchange Chemicals. (Aberdeen Proving Ground, MD 21010) Volume(issue)/page/year: NX#02407 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X5162 No. of Facilities: 7 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 28 (estimated)

Safety Information

[ Symbol ]:

GHS05

[ Signal Word ]:
Danger

[ Hazard Statements ]:
H314

[ Precautionary Statements ]:
P280-P305 + P351 + P338-P310

[ Personal Protective Equipment ]:
Eyeshields;Faceshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges

[ Hazard Codes ]:
C:Corrosive;

[ Risk Phrases ]:
R34

[ Safety Phrases ]:
S26-S36/37/39-S45

[ RIDADR ]:
UN 3261 8/PG 2

[ WGK Germany ]:
2

[ RTECS ]:
AM6950000

[ Packaging Group ]:
III

[ Hazard Class ]:
8

[ HS Code ]:
29147090

Synthetic Route

Click to get detail synthetic route

Precursor & DownStream

Precursor

DownStream

Customs

[ HS Code ]: 2914700090

[ Summary ]:
HS: 2914700090 halogenated, sulphonated, nitrated or nitrosated derivatives of ketones and quinones, whether or not with other oxygen function Tax rebate rate:9.0% Supervision conditions:none VAT:17.0% MFN tariff:5.5% General tariff:30.0%

Articles

Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: clues for specific design of new compounds.

J. Med. Chem. 54 , 4042-56, (2011)

Development of kinase-targeted therapies for central nervous system (CNS) diseases is a great challenge. Glycogen synthase kinase 3 (GSK-3) offers a great potential for severe CNS unmet diseases, bein...

Identification and characterisation of novel inhibitors on extrinsic tenase complex from Bungarus fasciatus (banded krait) venom.

Thromb. Haemost. 112(4) , 700-15, (2014)

Snake venoms are excellent sources of pharmacologically active proteins and peptides, and hence are potential sources of leads for drug developments. It has been previously established that krait (Bun...

Effects of vipoxin and its components on HepG2 cells.

Toxicon 94 , 36-44, (2015)

Snake venom Phospholipases A2 (svPLA2) are among the main toxic venom components with a great impact on different tissues and organs based on their catalytic specificity and a variety of pharmacologic...